Spots Global Cancer Trial Database for A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)
Official Title: A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer.
Study ID: NCT01655992
Conditions
Study Description
Brief Summary: Comparing S1 generic With Capecitabine in Patients With Metastatic Breast Cancer.
Detailed Description: Comparing S1 generic(Tegafur，Gimeracil and Oteracil Potassium Capsules) With Capecitabine in Patients With Metastatic Breast Cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Contact Details
Name: Xi-chun Hu, MD,PhD
Affiliation: Fudan Univeristy Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
